Patient Stories|VPRIV® (velaglucerase alfa) for injection

FEEL EMPOWERED TO PRESCRIBE
VPRIV AS A FIRST-LINE TREATMENT
FOR YOUR TYPE 1 GAUCHER PATIENTS

Make VPRIV your choice for patients during various stages of life.^1,2

ALISON

Name: Alison
Age: 28
Age at type 1 Gaucher diagnosis: 22
Ethnicity: Mixed race
current therapy:
VPRIV, 2 years
Treatment History:
VPRIV (3 years), SRT (7 months)
Symptoms at baseline:
Mildly enlarged spleen, mild thrombocytopenia, low hemoglobin³

^*Not an actual patient. This is a hypothetical patient profile.

Name: Alison
Age: 28
Age at type 1 Gaucher diagnosis: 22
Ethnicity: Mixed Race
current therapy: VPRIV, 2 years
Treatment History: VPRIV (3 years), SRT (7 months)
Symptoms at baseline:
Mildly enlarged spleen, mild thrombocytopenia, low hemoglobin³

Alison was diagnosed with type 1 Gaucher when she was 22 years old, after experiencing moderate anemia and fatigue.³

After speaking with her doctor about risks and benefits of treatment, she and her doctor chose VPRIV. She was treated with VPRIV for several years at an infusion center and then switched to substrate reduction therapy (SRT) when it became available. After some time on SRT she elected to switch back to VPRIV and has remained on VPRIV since.

Alison’s career demands much of her time, so she now receives her 60-minute VPRIV infusion at home.⁴

Consider

VPRIV is a 60-minute infusion taken once every other week, which may be administered at home under the supervision of a healthcare professional.⁴

See the Dosing and Infusion Guide for more information.

VPRIV Dosing & Infusion Guide

Looking to start your patients on VPRIV? Start the process by downloading a OnePath^® Start Form and filling it in with your patients to begin. Please contact OnePath^® at 1-866-888-0660 with any questions.

VPRIV OnePath® Start Form

Download the full VPRIV Patient Profiles here.

VPRIV Patient Profiles

VPRIV
Clinical Trials

Safety &
Tolerability Profile

Takeda Support Programs

STAY CONNECTED!

Fill in the required fields to stay up to date with news and announcements about VPRIV.

FIRST NAME*

LAST NAME*

EMAIL ADDRESS*

*By checking this box and clicking “Submit,” you certify that you are at least 18 years old, a US resident, and you are opting to receive information about VPRIV and other information from Takeda. You will be able to opt out of these communications using the unsubscribe feature.

Takeda respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Notice Statement. We encourage you to read our Privacy Notice Statement. This consent will be in effect until such a time as you opt out of the program.

FEEL EMPOWERED TO PRESCRIBE VPRIV AS A FIRST-LINE TREATMENT FOR YOUR TYPE 1 GAUCHER PATIENTS

Consider

FEEL EMPOWERED TO PRESCRIBE
VPRIV AS A FIRST-LINE TREATMENT
FOR YOUR TYPE 1 GAUCHER PATIENTS